Bromide

Bromide

SCHEMBL1194085

O=C(C[n+]1ccc(C(=O)NCCOC(=O)c2ccccc2)cc1)c1ccccc1.[Br-]

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.64
HPGD P15428 2/20 0.55
KMT2A Q03164 4/20 0.53
MEN1 O00255 3/20 0.53
KDM4E B2RXH2 4/20 0.52
MAPT P10636 4/20 0.52
POLB P06746 3/20 0.52
RAB9A P51151 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.50
LMNA P02545 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
GLA P06280 1/20 0.49
GAA P10253 1/20 0.48
NR4A1 P22736 1/20 0.48
BLM P54132 1/20 0.48
NPC1 O15118 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6228373 0.99 ALDH1A1 (0.61) ALDH1A1HPGDKMT2AMEN1KDM4E
Bromide SCHEMBL1194186 0.87 ALDH1A1 (0.53) ALDH1A1HPGDKMT2AMEN1KDM4E
Bromide SCHEMBL1194184 0.86 ALDH1A1 (0.51) ALDH1A1HPGDKMT2AMEN1KDM4E
SCHEMBL6908991 0.85 ALDH1A1 (0.53) ALDH1A1HPGDKMT2AMEN1KDM4E
SCHEMBL6227338 0.84 NPSR1 (0.60) ALDH1A1HPGDKMT2AMEN1POLB
SCHEMBL6227945 0.84 HPGD (0.52) ALDH1A1HPGDKMT2AMEN1KDM4E
SCHEMBL13100724 0.84 HPGD (0.74) ALDH1A1HPGDKMT2AMEN1MAPT
Hydrochloric Acid SCHEMBL1194141 0.83 NPSR1 (0.58) ALDH1A1HPGDKMT2AMEN1POLB
Bromide SCHEMBL1193999 0.77 GLA (0.58) ALDH1A1HPGDKMT2AMEN1KDM4E
Bromide SCHEMBL1193914 0.76 ALDH1A1 (0.51) ALDH1A1HPGDKMT2AMEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2659933-A1 Pharmaceutical combinations comprising specified age breaker and further drugs, i.a. antihypertensive drugs, antidiabetic drugs etc. Torrent Pharmaceuticals Ltd. (IN) 2013-11-06 EP claimed
JP-2011510067-A 2011-03-31 JP claimed
US-20110034378-A1 Pharmaceutical Combinations Comprising Specified Age Breaker and Further Drugs, I.A. Antihypertensive Drugs, Antidiabetic Drugs Etc. TORRENT PHARMACEUTICALS LTD. (IN) 2011-02-10 US claimed
EP-2254563-A2 PHARMACEUTICAL COMBINATIONS COMPRISING SPECIFIED AGE BREAKER AND FURTHER DRUGS, I.A. ANTIHYPERTENSIVE DRUGS, ANTIDIABETIC DRUGS ETC Torrent Pharmaceuticals Ltd. (IN) 2010-12-01 EP claimed
WO-2009093264-A2 PHARMACEUTICAL COMBINATIONS TORRENT PHARMACEUTICALS LTD. (IN) 2009-07-30 WO claimed
EP-1243581-B1 Pyridinium compounds useful for the treatment of AGE-related diseases TORRENT PHARMACEUTICALS LTD (IN) 2005-07-13 EP claimed
EP-1304101-A1 Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications Torrent Pharmaceuticals Ltd (IN) 2003-04-23 EP claimed
US-20030032660-A1 Breaking preformed AGE TORRENT PHARMACEUTICALS LTD. 2003-02-13 US claimed
EP-1243581-A1 Pyridinium compounds useful for the treatment of AGE-related diseases Torrent Pharmaceuticals Ltd (IN) 2002-09-25 EP claimed
US-20020103228-A1 Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications TORRENT PHARMACEUTICALS LTD. 2002-08-01 US claimed
EP-2659933-A1 Pharmaceutical combinations comprising specified age breaker and further drugs, i.a. antihypertensive drugs, antidiabetic drugs etc. Torrent Pharmaceuticals Ltd. (IN) 2013-11-06 EP disclosed
US-20110034378-A1 Pharmaceutical Combinations Comprising Specified Age Breaker and Further Drugs, I.A. Antihypertensive Drugs, Antidiabetic Drugs Etc. TORRENT PHARMACEUTICALS LTD. (IN) 2011-02-10 US disclosed
EP-1243581-B1 Pyridinium compounds useful for the treatment of AGE-related diseases TORRENT PHARMACEUTICALS LTD (IN) 2005-07-13 EP disclosed
EP-1304101-A1 Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications Torrent Pharmaceuticals Ltd (IN) 2003-04-23 EP disclosed
US-20030032660-A1 Breaking preformed AGE TORRENT PHARMACEUTICALS LTD. 2003-02-13 US disclosed
EP-1243581-A1 Pyridinium compounds useful for the treatment of AGE-related diseases Torrent Pharmaceuticals Ltd (IN) 2002-09-25 EP disclosed
US-20020103228-A1 Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications TORRENT PHARMACEUTICALS LTD. 2002-08-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030032660-A1 Breaking preformed AGE AGER, GPX1, RBP1 ALDH1A1 1451/4885HPGD 855/4885KMT2A 4457/4885
US-20020103228-A1 Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications PNPO, PRDX5, PLPBP ALDH1A1 662/4885HPGD 611/4885KMT2A 3459/4885
US-20110034378-A1 Pharmaceutical Combinations Comprising Specified Age Breaker and Further Drugs, I.A. Antihypertensive Drugs, Antidiabetic Drugs Etc. AGER, F12, DPP4 ALDH1A1 528/4885HPGD 3304/4885KMT2A 3384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.